

# Personalized Medicine Market to reach \$162 billion with 8.74% CAGR Analysis and Forecast to 2022

*Personalized Medicine Market to Grow at a 8.74% CAGR Key Player, Regions and Forecast to 2022*

PUNE, INDIA, June 12, 2017

/EINPresswire.com/ -- Description

[Personalized Medicine](#). Targeted Therapeutics and Companion Diagnostic Market- A Strategic Analysis of Industry Trends, Technologies, Participants, and Environment to 2021" (published May 2017)

Research forecasts that the companion diagnostic and targeted therapeutic submarkets of the personalized medicine industry were worth \$113 billion in 2016, and will hit over \$162 billion by 2021 with a CAGR of 8.74%. The total personalised therapeutic market, for all indications, will be worth \$x billion by 2021, with a CAGR of x%.

Currently it is estimated that the companion diagnostic segment is worth \$x billion globally, mainly coming from oncology, cardiovascular and infectious disease (HIV/HCV) tests. This is set to rise vertically over the next five years and by 2021 will be worth over \$x billion, with a CAGR of x%.



GET SAMPLE REPORT @ <https://www.wiseguyreports.com/sample-request/1309114-personalized-medicine-targeted-therapeutics-companion-diagnostic-market-to-2021>

Advancing technologies within the liquid biopsy market is also driving the market and will see strategic growth over the next five years with a CAGR of 20.6%. The two segments of the liquid biopsy market are tumor cell enrichment products and tumor cell detection technologies. Individualized, targeted or personalized medicine aims to increase the efficacy of therapeutics via genetic testing and companion diagnostics. Personalized therapeutics and associated companion diagnostics are more specific and effective thereby giving pharma/biotech companies a significant advantage to recuperate R&D costs. Personalized medicine reduces the frequency of adverse drug reactions and therefore has a dramatic impact on health economics. Developmental and diagnostic companies benefit from lower discovery and commercialization costs and more specific market subtypes.

This new report gives a comprehensive account of the market size, segmentation, key players, SWOT analysis, influential technologies, and business and economic environments. The report is supported by over 360 tables & figures over 397 pages. The personalized medicine market is presented as follows:

By Company (e.g., QIAGEN, AFFYMETRIX, ATOSSA GENETICS, NODALITY, deCode /Amgen, CELERA, MYRIAD)

By Segment (Targeted therapeutics, Companion Diagnostics)

By Sub-market (Companion diagnostic, targeted cancer therapeutic, medical technology,

pharmacogenomics, consumer genomics, molecular diagnostics, liquid biopsy)

By Therapy (Cancer, Cardiovascular, Infectious Disease)

Key Opinion Leaders that contributed to interview questions within the report include:

Iain D. Miller, PhD, MBA, Founder & CEO, Healthcare Strategies Group

Stephen Finn, MBBS, PhD, Associate Professor, Cancer Molecular Diagnostic Laboratory, Consultant Histopathologist and Head of Histopathology, St James's Hospital and Trinity College Dublin, Ireland

Ronald Przygodzki, MD, Director, Genomic Medicine Implementation at U.S. Department of Veterans Affairs, Washington DC

Elaine Kenny, PhD, Founder, Elda Biotech, Dublin, Ireland

Chad Clark, Co-President and Chief Operating Officer, Precision for Medicine

Tobias Guennel, PhD, Principal, Biomarker and IVD Analytics, Precision for Medicine

David Parker, PhD, Vice President, Integrated Market Access, Precision for Medicine

Deborah Phippard, PhD, Vice President, Research, Precision for Medicine

Judi Smith, MS, Vice President, In Vitro Diagnostics Regulatory and Quality, Precision for Medicine

A wealth of financial data & business strategy information is provided including:

Company Financials, Sales & Revenue Figures

Business Model Strategies for Diagnostic, Pharmaceutical and Biotechnology Companies

Business Model Strategies for Providers. Provider Systems and Academic Medical Centres

Business Model Strategies for Payers & Governments

Private and Public Funding and Personalized Medicine Reimbursement

Revisions to Current Payment Systems and Intellectual Property

How to Gain Market Penetration in the EU

Cost-effectiveness and Business Value of Personalized Medicine

Consumer genomics and POC market

Therapeutics and Companion Diagnostics (e.g., BRAC Analysis, Oncotype Dx , KRAS Mutations)

Comprehensive Account of Company Product Portfolios & Kits

SWOT, Economic & Regulatory Environment specifics include:

Key Strengths, Weaknesses and Threats Influencing Leading Player Position within the Market

Technologies Driving the Market (e.g., New-Generation Sequencing Technologies, Ultra-High Throughput Sequencing)

Top Fastest Growing Market Segments and Emerging Opportunities

Top Pharmaceutical Companies within the IPM by Market Share and Revenue

Comprehensive Product Portfolios, R&D Activity and Pipeline Therapeutics

M&A Activity and Future Strategies of Top Personalized Medicine Pharmacos

Personalized Medicine Regulation (UK, Germany, France, Spain, Italy)

CE-Marked Personalized Medicine/Diagnostic Tests

FDA Advances in Personalized Medicine Regulation

This report highlights a number of significant players and influential company's and gives details of their operations, products, financials and business strategy.

23andMe

Abbott Laboratories

Abbott Molecular Inc.

Admera Health (GENEWIZ)

Affymetrix

Agendia

Alere

Amgen

Astex Pharmaceuticals

AstraZeneca

Atossa Genetics

Becton Dickenson

bioMerieux

BristolMyersSquibb

Cancer Genetics

Celera (Quest Diagnostics)  
Celldex Therapeutics  
Claritas Genomics  
CuraGen  
Danaher (Leica Biosystems)  
deCode Genetics (Amgen)  
Foundation Medicine  
EDP Biotech  
Eli Lilly  
ELDA BioTech  
Eisai  
Genelex  
GlaxoSmithKline  
Human Longevity Inc (Cypher Genomics)  
HalioDx  
Ikonisys  
Illumina  
InterGenetics  
Johnson & Johnson  
LabCorp  
Life Technologies  
Merck  
MDxHealth  
MolecularMD Corporation  
Monogram Biosciences  
Myriad  
Nodality  
Novartis MDx  
Orion Genomics  
Oxford BioTherapeutics  
NanoString Technologies  
Pfizer  
Qiagen

Updates on the personalized medicine, targeted therapeutic and companion diagnostic space have been included in this latest edition to include cutting edge material from international conferences, workshops and symposia.

Who should read this report?

Pharmaceutical, biotechnology and diagnostic companies with an interest in personalized medicine

Industry professionals and business strategists will discover key information to propel their policies

Investors will gain inside information to dominant players in the industry and future forecasts  
Scientists will get a business perspective and industry insight into how scientific breakthroughs influence the market environment

This report will tell you if the companies mentioned are:

Strong, competitive players

Pooling their resources for specific growth and therapeutic areas

Investing strategically in R&D

Have a history of strategic M&A activity

This detailed report is supported with over 365 tables & figures over 397 pages and profiles the main pharmacos in personalized medicine.

Table of Content: Key Points

Executive Summary

1.1 Objectives of Report

- 1.2 Scope of Study
  - 1.3 Data Sources and Methodology
  - 1.4 Key Findings and Observations
    - 1.4.1 CYP2C9 and VKORC1 mutations and Warfarin Response
    - 1.4.2 KRAS Mutations
    - 1.4.3 Herceptin® and Breast Cancer
    - 1.4.4 BRACAnalysis®
- ...Continued□

ACCESS REPORT @ <https://www.wiseguyreports.com/reports/1309114-personalized-medicine-targeted-therapeutics-companion-diagnostic-market-to-2021> □

Get in touch:

LinkedIn: [www.linkedin.com/company/4828928](http://www.linkedin.com/company/4828928)

Twitter: <https://twitter.com/WiseGuyReports> □

Facebook: <https://www.facebook.com/Wiseguyreports-1009007869213183/?fref=ts>

Norah Trent

Wise Guy Consultants Pvt. Ltd.

+1 (339) 368 6938 (US)/+91 841 198 5042 (IND)

[email us here](#)

---

This press release can be viewed online at: <http://www.einpresswire.com>

Disclaimer: If you have any questions regarding information in this press release please contact the company listed in the press release. Please do not contact EIN Presswire. We will be unable to assist you with your inquiry. EIN Presswire disclaims any content contained in these releases. © 1995-2019 IPD Group, Inc. All Right Reserved.